<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="208539">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00373243</url>
  </required_header>
  <id_info>
    <org_study_id>CXA100754</org_study_id>
    <nct_id>NCT00373243</nct_id>
  </id_info>
  <brief_title>A Study Of GW406381 In Volunteers With Moderate Hepatic Impairment</brief_title>
  <official_title>An Open-Label, Non-Randomised Study of 20 mg GW406381 Single Dose Pharmacokinetics in Healthy Subjects and in Volunteers With Moderate Hepatic Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This study will assess the pharmacokinetics and tolerability of a single dose of GW406381 in
      subjects with moderate hepatic impairment in comparison to matched healthy volunteers. The
      hepatically impaired and healthy groups will be given a single 20 mg oral dose of GW406381.
      Blood samples for PK analysis will be collected pre-dose and over the 72 hours post dosing.
      Subjects will be housed from the evening before dosing until 24 hours after dosing. A
      follow-up visit will be conducted between 7 to 10 days from the last dose of study drug.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>GW406381 pharmacokinetic parameters AUC and Cmax</measure>
    <time_frame>throughout the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>GW406381 pharmacokinetic parameters Tmax, Total plasma clearance, and if data permits the t1/2 of GW406381 GW404347 pharmacokinetic parameters AUC and Cmax Ex vivo protein binding Clinical laboratory values, adverse events, vital signs and 12 lead ECG</measure>
    <time_frame>throughout the study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Hepatic Insufficiency</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GW406381</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Healthy subjects or subjects with moderate hepatic impairment as defined by a
             Child-Pugh score of 7-9

          -  Body weight less = 100 kg

          -  Body mass index (BMI) within range of 19 - 32 32kg/m2

        Exclusion criteria:

          -  Presence of any other significant disease

          -  Use of any medication within the 2 weeks prior to dosing, unless approved by both the
             investigator and GSK personnel
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials, MD</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Balantonfured</city>
        <zip>8230</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>1062</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <lastchanged_date>May 15, 2009</lastchanged_date>
  <firstreceived_date>September 5, 2006</firstreceived_date>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>GSK</organization>
  </responsible_party>
  <keyword>hepatic impairment pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Hepatic Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
